The finale of my short story, A Cure for Melancholy is out on my Substack, "What Survives." Please subscribe to my newsletter for free to receive new posts and support my work. I have new posts (essays, short stories, etc.) twice a month. https://t.co/f8BnnlBZRI
The second of my three-part short story, A Cure for Melancholy, has posted today on my Substack newsletter, What Survives, at https://t.co/FPyOUjDzXk
Please subscribe to What Survives and join me on this journey.
I’ve started my own Substack Newsletter, What Survives at https://t.co/FPyOUjDzXk
This newsletter is my space to explore the questions that emerge while writing my novels – questions about science, ethics, spirituality, and the human longing to transcend.
@AlokPatelMD Dr. Mark Rubinstein, Executive Medical Officer at JUUL Labs; will be in NY August 13-14 . Would you like to meet him to discuss JUUL Labs’ preclinical/toxicology, clinical, and behavioral research? [email protected]
@DrJohnTorres Dr. Mark Rubinstein, Executive Medical Officer at JUUL Labs, will be in New York on Aug. 13-14. Would you like to meet with him to discuss JUUL Labs’ preclinical/toxicology, clinical, and behavioral research? [email protected]
@jwgale Hi Jason. Are you covering ISN/WCN in Melbourne. Do you know about Monday's late-breaker session with CREDENCE -- the first study to show a diabetes drug can stop progression of chronic kidney disease. Email me at [email protected]. I'm handling media outreach on this.